Ranibizumab port delivery system: a clinical perspective

Area of Science:

• Ophthalmology
• Retinal Diseases
• Drug Delivery Systems

Background:

• Age-related macular degeneration (AMD) is a primary cause of vision loss globally.
• Neovascular AMD (nAMD) management relies on frequent intravitreal anti-vascular endothelial growth factor (aVEGF) injections, posing a significant treatment burden.
• The need for less burdensome, durable treatment options for nAMD is critical in clinical practice.

Purpose of the Study:

• To review the ranibizumab port delivery system (PDS) as a sustained-release treatment for nAMD.
• To evaluate the clinical trial data, safety profile, and real-world potential of the PDS.
• To discuss other emerging sustained-treatment modalities for nAMD.

Main Methods:

• Review of Phase II and III clinical trial data for the ranibizumab port delivery system (PDS).
• Analysis of safety and adverse event profiles associated with the PDS.
• Discussion of real-world clinical application and comparison with existing therapies.

Main Results:

• The PDS demonstrated non-inferiority to monthly ranibizumab injections in clinical trials.
• The PDS allows for sustained release of ranibizumab with refill intervals of up to 6 months.
• FDA approval was granted for the PDS, marking a significant advancement in nAMD treatment intervals.

Conclusions:

• The ranibizumab port delivery system (PDS) provides a durable and effective treatment option for neovascular AMD, addressing the limitations of frequent injections.
• The PDS offers a reduced treatment burden for patients with nAMD, potentially improving adherence and long-term outcomes.
• Further evaluation of sustained-treatment modalities, including the PDS, is essential for optimizing nAMD management.